vs
Side-by-side financial comparison of Community West Bancshares (CWBC) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
Community West Bancshares is the larger business by last-quarter revenue ($38.3M vs $28.1M, roughly 1.4× ARS Pharmaceuticals, Inc.). On growth, Community West Bancshares posted the faster year-over-year revenue change (11.6% vs -67.6%).
Community West BancsharesCWBCEarnings & Financial Report
Community West Bancshares is a registered bank holding company headquartered in California. It wholly owns Community West Bank under the Bank Holding Company Act.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
CWBC vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $28.1M |
| Net Profit | — | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | 40.0% | -147.6% |
| Net Margin | — | -147.1% |
| Revenue YoY | 11.6% | -67.6% |
| Net Profit YoY | — | -182.8% |
| EPS (diluted) | $0.58 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $28.1M | ||
| Q3 25 | $37.9M | $32.5M | ||
| Q2 25 | $35.7M | $15.7M | ||
| Q1 25 | $34.8M | $8.0M | ||
| Q4 24 | $34.3M | $86.6M | ||
| Q3 24 | $31.3M | $2.1M | ||
| Q2 24 | $30.5M | $500.0K | ||
| Q1 24 | $20.7M | $0 |
| Q4 25 | — | $-41.3M | ||
| Q3 25 | $10.9M | $-51.2M | ||
| Q2 25 | $7.8M | $-44.9M | ||
| Q1 25 | $8.3M | $-33.9M | ||
| Q4 24 | — | $49.9M | ||
| Q3 24 | $3.4M | $-19.1M | ||
| Q2 24 | $-6.3M | $-12.5M | ||
| Q1 24 | $3.7M | $-10.3M |
| Q4 25 | 40.0% | -147.6% | ||
| Q3 25 | 39.8% | -163.7% | ||
| Q2 25 | 30.2% | -302.9% | ||
| Q1 25 | 32.7% | -466.3% | ||
| Q4 24 | 31.0% | 54.5% | ||
| Q3 24 | 13.3% | -1051.6% | ||
| Q2 24 | -25.9% | -3068.0% | ||
| Q1 24 | 23.2% | — |
| Q4 25 | — | -147.1% | ||
| Q3 25 | 28.7% | -157.4% | ||
| Q2 25 | 22.0% | -285.6% | ||
| Q1 25 | 23.8% | -425.7% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | 10.8% | -925.0% | ||
| Q2 24 | -20.7% | -2503.2% | ||
| Q1 24 | 17.8% | — |
| Q4 25 | $0.58 | $-0.41 | ||
| Q3 25 | $0.57 | $-0.52 | ||
| Q2 25 | $0.41 | $-0.46 | ||
| Q1 25 | $0.44 | $-0.35 | ||
| Q4 24 | $0.29 | $0.52 | ||
| Q3 24 | $0.18 | $-0.20 | ||
| Q2 24 | $-0.33 | $-0.13 | ||
| Q1 24 | $0.31 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $119.0M | $245.0M |
| Total DebtLower is stronger | $69.5M | $96.4M |
| Stockholders' EquityBook value | $409.6M | $114.3M |
| Total Assets | $3.7B | $327.7M |
| Debt / EquityLower = less leverage | 0.17× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $119.0M | $245.0M | ||
| Q3 25 | $121.6M | $288.2M | ||
| Q2 25 | $134.4M | $240.1M | ||
| Q1 25 | $148.4M | $275.7M | ||
| Q4 24 | $120.4M | $314.0M | ||
| Q3 24 | $149.0M | $204.6M | ||
| Q2 24 | $109.7M | $218.7M | ||
| Q1 24 | $61.0M | $223.6M |
| Q4 25 | $69.5M | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $69.9M | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $409.6M | $114.3M | ||
| Q3 25 | $397.6M | $147.7M | ||
| Q2 25 | $380.0M | $192.3M | ||
| Q1 25 | $372.2M | $229.0M | ||
| Q4 24 | $362.7M | $256.8M | ||
| Q3 24 | $363.5M | $201.0M | ||
| Q2 24 | $350.2M | $215.2M | ||
| Q1 24 | $211.7M | $223.9M |
| Q4 25 | $3.7B | $327.7M | ||
| Q3 25 | $3.6B | $372.8M | ||
| Q2 25 | $3.6B | $313.5M | ||
| Q1 25 | $3.6B | $327.3M | ||
| Q4 24 | $3.5B | $351.2M | ||
| Q3 24 | $3.5B | $217.6M | ||
| Q2 24 | $3.5B | $222.0M | ||
| Q1 24 | $2.4B | $227.6M |
| Q4 25 | 0.17× | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.19× | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.1M | $-43.5M |
| Free Cash FlowOCF − Capex | $43.6M | — |
| FCF MarginFCF / Revenue | 113.9% | — |
| Capex IntensityCapex / Revenue | 6.6% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $46.1M | $-43.5M | ||
| Q3 25 | $13.2M | $-47.0M | ||
| Q2 25 | $11.5M | $-39.6M | ||
| Q1 25 | $11.1M | $-40.7M | ||
| Q4 24 | $22.2M | $42.0M | ||
| Q3 24 | $7.8M | $-14.5M | ||
| Q2 24 | $5.2M | $-7.3M | ||
| Q1 24 | $4.0M | $-6.7M |
| Q4 25 | $43.6M | — | ||
| Q3 25 | $12.8M | $-47.2M | ||
| Q2 25 | $10.6M | $-39.6M | ||
| Q1 25 | $10.8M | $-40.8M | ||
| Q4 24 | $17.2M | $41.7M | ||
| Q3 24 | $5.2M | $-14.6M | ||
| Q2 24 | $4.8M | $-7.3M | ||
| Q1 24 | $3.6M | $-6.8M |
| Q4 25 | 113.9% | — | ||
| Q3 25 | 33.7% | -145.4% | ||
| Q2 25 | 29.6% | -252.2% | ||
| Q1 25 | 30.9% | -512.1% | ||
| Q4 24 | 50.0% | 48.2% | ||
| Q3 24 | 16.7% | -706.3% | ||
| Q2 24 | 15.7% | -1463.4% | ||
| Q1 24 | 17.3% | — |
| Q4 25 | 6.6% | 0.0% | ||
| Q3 25 | 1.1% | 0.6% | ||
| Q2 25 | 2.7% | 0.3% | ||
| Q1 25 | 0.9% | 1.1% | ||
| Q4 24 | 14.7% | 0.3% | ||
| Q3 24 | 8.1% | 6.8% | ||
| Q2 24 | 1.4% | 7.6% | ||
| Q1 24 | 2.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.21× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.33× | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | 2.29× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CWBC
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
